A new study released Monday said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally ...

Merck made a formal request for Emergency Use Authorization from the FDA Monday for its COVID-19 pill treatment, known as molnupiravir. Merck (MRK) said Monday it has submitted a formal ...

An FDA advisory committee voted by 13 to 10 to recommend emergency-use authorisation for Merck & Co and Ridgeback's oral antiviral molnupiravir for mild-to-moderate COVID-19, saying it would be ...

Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

While Merck and its partner Ridgeback Biotherapeutics were the first to submit their COVID-19 pill to the FDA, rival drugmaker Pfizer is close behind with its own pill under review.

The first-ever COVID-19 pill could be available before the end of the year. This week, Merck and Ridgeback Biotherapeutics asked the Food and Drug Administration (FDA) to authorize their antiviral ...

The Food and Drug Administration approved the latest Covid vaccines yesterday ... Columbia that bears the Vagelos family name. A former Merck CEO, Roy Vagelos is the child of Greek immigrants ...

WASHINGTON--Drugmaker Merck asked U.S. regulators Monday ... first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require an IV or injection.

The FDA authorized Merck’s drug for adults with a positive COVID-19 test, early symptoms and who face the highest risks of hospitalization, including older people and those with conditions like ...

Efforts to find an easy, early COVID-19 treatment may ... can’t emerge because the drug makes too many other damaging mutations,” Denison says. Merck says it can make as many as 10 million ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...